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Abstract
Objective:
The goal of this study was to validate a previously derived and identified physiological subcutaneous (SC) 
insulin absorption model for computer simulation in a clinical diabetes decision support role using published 
pharmacokinetic summary measures.
Methods:
Validation was performed using maximal plasma insulin concentration (Cmax) and time to maximal concentration 
(tmax) pharmacokinetic summary measures. Values were either reported or estimated from 37 pharmacokinetic 
studies over six modeled insulin types. A validation comparison was made to equivalent pharmacokinetic 
summary measures calculated from model generated curves fitted to respective plasma insulin concentration 
data. The validation result was a measure of goodness of fit. Validation for each reported study was classified 
into one of four cases.
Results:
Of 37 model fits, 22 were validated on both the Cmax and the tmax summary measures. Another 6 model fits 
were partially validated on one measure only due to lack of reporting on the second measure with errors to 
reported or estimated ranges of <12%. Another 7 studies could not be validated on either measure because 
of inadequate reported clinical data. Finally, 2 separate model fits to data from the same study failed the 
validation with 90 and 71% error on tmax only, which was likely caused by protocol-based error. No model fit 
failed the validation on both measures.
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Introduction
This study reports the validation of an identified 
physiological compartment model of plasma insulin 
appearance from subcutaneous (SC) injection that is 
presented in this journal. A range of clinically current 
insulin types were modeled, specifically the prandial 
insulins monomeric insulin (MI) and regular insulin 
(RI) and the intermediate- and long-acting basal insulins 
neutral protamine Hagedorn (NPH) and glargine. The 
older insulin types lente and ultralente were also 
modeled. This facility enabled retrospective data of 
patients treated with these insulin types to be used 
for model identification and validation. The model was 
identified previously with good precision in all identified 
parameters using a wide range of clinical data, and this 
validation study aims to gauge the accuracy of this model 
identification using published pharmacokinetic summary 
measures.
If the intended role of the model is in silico simulation, 
a Monte Carlo analysis will be used to simulate 
physiological variability in the pharmacokinetic (PK) 
profile by transforming published variability (in 
coefficient of variation) in the key PK summary measures 
from clinical studies into model parameter probability 
distributions about the mean parameters identified 
from mean data. This approach differs from the normal 
approach of identifying the model on a small cohort of 
individual patient data, as the amount of information 
considered is considerably higher and the potential for 
more accurate simulation is greater.
Model Validation
Data used for model identification and now validation 
were collected via a literature review of relevant insulin 
PK studies searched in the MEDLINE and Science 
Citation Index Expanded (SCI-EXPANDED) databases. 
Only studies using direct measurement methods were 
considered.1 These studies differ widely in cohort 
studied, methods, and protocol. However, data suffice 
for this study where the goal is to develop a mean PK 
simulation model for a diabetes decision support system. 
A parameter fit and validation across a broad range of 
studies are likelier to result in an averaged PK response 
suitable for clinical use over a wide population. However, 
there are potentially three factors that may affect the 
accuracy of data:
Insulin antibodies [insulin-dependent diabetes mellitus 
(IDDM) cohort only]
Endogenous insulin production (noninsulin-dependent 
diabetes mellitus and normal cohorts only)
Insufficient cross-reactivity of test insulin with insulin 
assay (insulin analogue and animal insulin studies 
only)
Because of an almost universal lack of availability of 
spread data for each time point in the majority of 
these studies, a simpler validation criterion is proposed. 
Referring to Figure 1, two common PK summary 
measures, time to maximal plasma insulin concentration 
(tmax) and maximal plasma insulin concentration (Cmax), 
for each fitted model curve (tmax,model and Cmax,model) 
can be compared to reported clinical values for each 
data set (tmax,data and Cmax,data). For these measures, a 
reported spread over the study for these two parameters 
(SDtmax,data and SDCmax,data) is used to validate the equivalent 
identified model and results. Other well-accepted 
measures, including t50 (half-time to and decrease from 
peak) and area under curve, are not always reported 
uniformly by all studies and were thus not used here.
1.
2.
3.
Abstract cont.
Conclusions:
A previously derived and identified model was clinically validated for six insulin types using Cmax and tmax 
summary measures from published pharmacokinetic studies. Hence, this article presents a clinically valid 
model that accounts for multiple nonlinear effects and six different types of SC insulin in a computationally 
modest form suitable for use in clinical decision support.
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While this validation criterion may not be fully rigorous, 
it is the only method to assess the model fit to data in 
the absence of other complete data over several studies. 
Summary measures such as these are also used very 
commonly for describing insulin PKs and were thus 
readily available for most studies, allowing validation 
criteria comparison across studies. Finally, tmax and Cmax 
describe the basic and fundamental clinical features of 
insulin action.
The result of this comparison is shown in Tables 1–6, 
and a summary is shown in Table 7. Where tmax or 
Cmax values are not reported in the study, they are 
calculated from the mean PK curves used for the 
parameter identification. All reported measures are unit 
standardized and expressed as mean ± SD if reported 
differently. Some values are baseline corrected to match 
data used for parameter identification. If a summary 
measure is not reported and bounds cannot be estimated 
from reported data or if only a mean value was reported 
with no variation or spread, then the model fit cannot be 
validated on that particular measure for that particular 
study.
Possible validation outcomes are therefore limited to the 
following cases for each study:
The model fit is fully validated if both model curve tmax 
and Cmax (tmax,model or Cmax,model) are within SDtmax  
and SDCmax
The model fit is considered partially validated if only 
Cmax,model lies outside ± SDCmax,data
If tmax,model lies outside tmax,data ± SDtmax,data , the model 
fit is invalidated regardless of Cmax,model. This case 
choice slightly emphasizes the qualitative shape of 
the model curve rather than the quantitative plasma 
insulin concentration.
Clearly, the model fit is also invalidated if both model 
curve tmax and Cmax (tmax,model or Cmax,model) are outside 
tmax,data ± SDtmax,data  and Cmax,data ± SDCmax,data
If Cmax,model cannot be validated but tmax,model lies 
within tmax,data ± SDtmax,data  or vice versa, the model fit 
is partially validated
If both tmax,model and Cmax,model cannot be validated, 
the model fit cannot be validated overall
In case of outcomes e and f, a percentage error is still 
calculated and shown in Table 7 to provide an estimate 
of reliability.
a.
b.
c.
d.
e.
f.
Monomeric Insulin Submodel Validation Summary
Referring to Tables 1 and 7, all MI model curve tmax and 
Cmax values are fully validated (outcome a) except for 
the study by Shimoda and colleagues,2 which cannot be 
validated (outcome f).
Figure 1. Schematic diagram of a plasma insulin model output curve 
with tmax,model and Cmax,model, and corresponding data set reported 
tmax,data and Cmax,data (with standard deviation SDtmax  and SDCmax, 
respectively).
Table 1.
Summary Measures for Fitted MI Model Curve 
Compared to Published Valuesa
Parameter
Reference
0   4
tmax 
(min)
Modeled 47 4 5 6
Literature 46.7 ± .0 .8 49.0 ± .
. ± 
.6
Cmax 
(mU/liter)
Modeled 6.8 . 9.0 .0
Literature 4. ± 4.5b 5.0 4.5 ± 4.5 4.6 ± 5.8
a Units are standardized from original reported units in literature, 
and values are transformed into mean ± SD if reported 
differently. Some values have been baseline corrected where 
necessary.
b Baseline corrected to match plotted data used for model 
parameter fit.
Regular Insulin Submodel Validation Summary
With reference to Tables 2 and 7 for RI data, the study 
by Davis and associates3 is invalidated (outcome c) with 
a very short tmax of 30.0 ± 7.9 minutes (for RI), resulting 
in 90 ± 26% error. This study underestimates tmax as it 
is not corrected for endogenous production, leading to 
overestimation of plasma insulin appearance in the early 
part of the trial where insulin production has not been 
fully suppressed. The 6U RI dose is also insufficient to 
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fully suppress insulin production, which is confirmed by 
the reported C-peptide measurements.3 Another study4 
is partially validated (outcome b) with 11.8% Cmax error 
considering that insulin antibodies were unaccounted 
for in the IDDM cohort. Finally, as for MI, the RI model 
fit to the study by Shimoda and colleagues2 cannot be 
validated due to a lack of fully reported data (outcome f). 
Neutral Protamine Hagedorn Submodel Validation 
Summary
For NPH data in Tables 3 and 7, poor model curve 
tmax values were also obtained for Davis et al.3 and 
Galloway et al.5 compared to reported values, as shown in 
Table 3. While the model fit to the study by Davis et al.3 
is invalidated (outcome c), the study by Galloway and 
colleagues5 is still fully validated because of the use of 
inadequate normal descriptive statistics for nonnormal 
data distribution. Similar to the RI study by Davis et al.,3 
these two study protocols are both uncorrected for 
endogenous insulin production and prescribe a relatively 
low dose (14 units and 0.25 U/kg, respectively) compared 
to other studies uncorrected for insulin production 
(0.4 U/kg6,7). Studies by Bottermann et al.6 and 
Heinemann et al.7 used higher comparative insulin doses, 
and Bottermann and colleagues6 reported a negligible 
serum C-peptide concentration for most of the study 
duration.
Lente and Ultralente Submodel Validation Summary
All lente model fits are fully validated (see Tables 4 and 7) 
as are all but two ultralente model fits (see Tables 5 and 7), 
where studies by Lepore et al.8 and Owens et al.9 are 
partially validated (outcome e) with 20.5 and 8.2% Cmax 
error, respectively.
Table 2.
Summary Measures for Fitted RI Model Curve Compared to Published Valuesa 
Parameter
Reference
5 6
7
 4 8
9

5
. 
U/ml
40 U/ml 40 U/ml
00 
U/ml
NPH 
study
Lente 
study
tmax 
(min)
Modeled 65 80 5 66 07 9 84 8  57 8 86
Literature 50–80b
8. ± 
4. 45–75
b 45–90b 84.0
.0 ± 
58.8
9.0 ± 
55.0
78.0 ± 
4.0
44.0 ± 
60.0
0.0 ± 
7.9
08.0 ± 
66.0
56.0 ± 
98.0
Cmax 
(mU/liter)
Modeled 59. 4.9 7. 6.0 0.5 7.0 0.8 9. 0.6 6. 87. 75.7
Literature 50–65b
5.4 ± 
.4c 65–90
b 54–8b 8.8
7.4–
.b
. ± 
6.0
8. ± 
4.6
.6 ± 
.0 4.5
b 70.5 ± 
.7
7.8 ± 
5.6
a Units are standardized from original reported units in literature, and values are transformed into mean ± SD if reported differently. Some 
values have been baseline corrected where necessary.
b Estimated from plotted data as value is not quoted in study.
c Baseline corrected to match plotted data used for model parameter fit.
Table 3.
Summary Measures for Fitted NPH Model Curve Compared to Published Valuesa
Parameter
Reference
0 8
 9
6  5 7
Clamp  Clamp  40 U/ml 00 U/ml
tmax (min)
Modeled 60  8 50 97   69 8 8
Literature 80–00b 40 4 ± 84 8 ± 80 88 ± 74 8 ± 76 40b 40 ± 56 76 ± 9 96 ± 64c
Cmax 
(mU/liter)
Modeled 7.8 .9 9.9 6. .5 9. 5.4 .0 7. .6
Literature 7.5b .8 ± 9.8 . ± 5.0 8.4 ± . 6. ± 7.8 . ± 4.4 6.b .0b .8 ± 8.8 0. ± 5.0c
a Units are standardized from original reported units in literature, and values are transformed into mean ± SD if reported differently. Some 
values have been baseline corrected where necessary.
b Estimated from plotted data as value is not quoted in study.
c Summary measures quoted by study not identical to plotted values due to differences in calculation method.
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Insulin Glargine Submodel Validation Summary
For insulin glargine (see Tables 6 and 7), Heinemann and 
associates7 reported measures calculated using a different 
method to plotted data and cannot be validated. Using 
the isoglycemic clamp method, another study8 corrected 
the plasma insulin concentration for insulin glargine 
(measured via nonspecific insulin assay) only from 3 
hours onward, after the intravenous (IV) insulin infusion 
rate had decreased to near nil. The origin of the insulin 
in plasma is thus indeterminate with IV insulin infusion 
in this time period. Unlike the reported Cmax (measured 
between 3 and 24 hours), all insulin measurements were 
used in the model parameter fit to data, which may have 
contributed to the Cmax error of 8.5 ± 6.9% (outcome e).
In summary, it can be seen that 22 model fits are fully 
validated using both reported tmax and Cmax summary 
measures, or estimated values from plotted data where 
not reported (see Table 7). A further 6 model fits are 
partially validated on tmax only (outcome b) or on Cmax 
only if tmax cannot be validated (outcome e). All partially 
validated model fits have errors not exceeding 12% of 
reported or estimated tmax or Cmax ranges. Validation 
cannot be performed for 7 model fits due to only a mean 
reported, or completely unreported, tmax and Cmax, and/or 
if a range of tmax and Cmax cannot be estimated from 
plotted data (outcome f). Even then, this error is <30%. 
Only 2 model fits failed validation with 90 ± 26 and 
71 ± 23% error on tmax only; in both cases, significant 
protocol-based reasons were identified and these errors 
are still <100%. These data was from the same study3 (for 
RI and NPH). No model fit was invalidated on both tmax 
and Cmax measures.
As an additional validation, sample model fits to MI10 
and insulin glargine8 data are shown in Figures 2 and 3. 
The model-generated curve using median or mean 
Table 4.
Summary Measures for Fitted Lente Model Curve 
Compared to Published Valuesa  
Parameter
Reference
5
tmax (min)
Modeled 00
Literature 0 ± 74
Cmax (mU/liter)
Modeled 5.6
Literature .0 ± 5.8
a Units are standardized from original reported units in literature, 
and values are transformed into mean ± SD if reported 
differently. Some values have been baseline corrected where 
necessary.
Table 5.
Summary Measures for Fitted Ultralente Model 
Curve Compared to Published Valuesa 
Parameter
Reference

8 9
Clamp  Clamp 
tmax 
(min)
Modeled 495 900 477 77
Literature 648 ± 00 86 ± 60 600 840
Cmax 
(mU/liter)
Modeled 4. 7.9 .0 7.0
Literature 6.4 ± 8. 4. ± 8.4
5.9 ± 
9.4
7.8 ± 6.0
a Units are standardized from original reported units in literature, 
and values are transformed into mean ± SD if reported 
differently. Some values have been baseline corrected where 
necessary.
Table 6.
Summary Measures for Fitted Glargine Model Curve Compared to Published Valuesa 
Parameter
Reference
8
0
7

80 μg/ml zinc 5 μg/ml zinc Clamp  Clamp 
tmax (min)
Modeled 56 554 74 50 780 777
Literature 80–440b 600c 840c 8 ± 5d 744 ± 70 660 ± 
Cmax (mU/liter)
Modeled 0.5 4. .8 7.0 7.9 8.0
Literature 8.9 ± .e 5.5c 4.8c . ± 4.d . ± 5.7 0.0 ± .5
a Units are standardized from original reported units in literature, and values are transformed into mean ± SD if reported differently. Some 
values have been baseline corrected where necessary.
b Plateau time (–4 hours).
c Estimated from plotted data as value is not quoted in study.
d Summary measures quoted by study not identical to plotted values due to differences in calculation method.
e Plateau concentration measured from  to 4 hours.
parameter values as an overall population value is shown 
in addition to the individual model fit curve. In both 
cases the results are excellent matches for data reported 
in these cases.
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Table 7.
Summary of Model Validation to Reported tmax and Cmax Summary Measures
Insulin 
type
Study
Within tmax bounds Within Cmax bounds Fully 
validated
Partially 
validated
Validation 
cannot be 
performed
Validation 
Failed
Yes No N/A Yes No N/A
MI 0 ✓ ✓ ✓
MI  ✓ (9%) ✓ (8%) ✓
MI  ✓ ✓ ✓
MI 4 ✓ ✓ ✓
RI 5 ✓ ✓ ✓
RI 6 ✓ ✓ ✓
RI 7 ✓ ✓ ✓
RI 7 ✓ ✓ ✓
RI  ✓ (7%) ✓ (9%) ✓
RI 4 ✓ ✓ (.8%) ✓ a
RI 8 ✓ ✓ ✓
RI 9 ✓ ✓ ✓
RI 9 ✓ ✓ ✓
RI  ✓ (90 ± 6%) ✓ (7%) ✓ a
RI 5 ✓ ✓ ✓
RI 5 ✓ ✓ ✓
NPH 0 ✓ ✓ (4%) ✓ a
NPH 8 ✓ (%) ✓ ✓ a
NPH  ✓ ✓ ✓
NPH  ✓ ✓ ✓
NPH 9 ✓ ✓ ✓
NPH 9 ✓ ✓ ✓
NPH 6 ✓ (%) ✓ (7%) ✓
NPH  ✓ (7 ± %) ✓ ✓ a
NPH 5 ✓ ✓ ✓
NPH 7 ✓ ✓ ✓ ✓
Lente 5 ✓ ✓ ✓
Ultralente  ✓ ✓ ✓
Ultralente  ✓ ✓ ✓
Ultralente 8 ✓ (%) ✓ ✓ a
Ultralente 9 ✓ (8%) ✓ ✓ a
Glargine 8 ✓ ✓ (8.5 ± 6.9 %) ✓ a
Glargine 0 ✓ (8%) ✓ (6%)
Glargine 0 ✓ (4%) ✓ (%) ✓
Glargine 7 ✓ ✓ ✓
Glargine  ✓ ✓ ✓ ✓
Glargine  ✓ ✓ ✓
a Refer to the text for a list of partial and failed validation outcomes.
7Autonomic Mechanisms and Therapeutic Implications of Postural Diabetic Cardiovascular Abnormalities Wong
www.journalofdst.orgJ Diabetes Sci Technol Vol , Issue 4, July 008
Model Simulation and Outputs
A comparison of model outputs using the population 
model parameters for an injection of 10 units for all 
insulin types is shown in Figure 4. Results are compared 
to output from the AIDA insulin PK model11 by Berger 
and Rodbard,12 which uses a nonlinear noncompartmental 
model. This model is one of the foremost SC insulin PK 
models developed for computer simulation of multiple 
insulin types and was subsequently applied in the 
AIDA diabetes education and decision support system. 
While the most complete of insulin models, it does not 
model MI or insulin glargine absorption, as it was first 
published in 1989 before these types were developed. 
Figure 2. MI model fit to data of Plank et al.10
Figure 3. Insulin glargine model fit to data of Lepore et al.8 Note that 
the plasma insulin concentration is corrected for cross-reactivity with 
insulin glargine only between 3 and 24 hours, i.e., the first three data 
points are inaccurate in respect to the exogenous insulin glargine 
concentration in plasma due to the presence of a not insignificant IV 
insulin infusion.
As shown in Figure 4, the dynamics of each modeled 
insulin type are visually similar between the two models, 
providing an additional measure of validation.
The model dynamics are also demonstrated for RI 
concentration dependency and insulin glargine dose 
dependency in Figure 5. For a given RI dose, the 
Figure 4. Comparison of model output and the AIDA insulin SC PK 
model for a 10-unit injection of all insulin types.11,12 Published in 1989, 
the AIDA model does not model MI or insulin glargine absorption.
Figure 5. Dynamics of RI concentration dependency and insulin 
glargine dose response demonstrated by the model.
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infusion or bolus subcutaneous injection in diabetic patients. 
Diabetes. 1983;32(4):331-6.
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12.
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14.
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17.
rate of absorption decreases with increasing insulin 
concentrations until 500 U/ml, where it begins to 
increase slightly. This latter phenomenon has not been 
reported in any study, although such high concentrations 
are rarely, if ever, used clinically. For a given dose, the 
absorption rate usually decreases with an increasing 
concentration of insulin preparation. However, while 
the mass in the hexameric state increases, the rate 
of diffusive loss, kd, from the dimeric/monomeric 
compartment drops markedly with decreasing injection 
volume, which ultimately results in an increasing net 
rate of absorption at very high concentrations of injected 
insulin concentration.
Conclusions
The identified model was validated using the simple 
widely reported criterion of tmax and Cmax PK summary 
measures reported the most consistently in these studies. 
Of 37 model fits, 22 were validated on both summary 
measures reported by each study or estimated from 
plotted data used for parameter fit where not reported. 
An additional 6 model fits were partially validated on 
tmax only or on Cmax if and only if tmax could not be 
validated. All partially validated model fits had errors 
not exceeding 12% of reported or estimated tmax or 
Cmax ranges. Another 7 studies could not be validated 
because of unreported data or reporting of only the 
mean values of tmax and Cmax and because a range of 
tmax and Cmax could not be estimated from data reported 
in the study. Finally, 2 model fits from the same study 
failed the validation with 90 and 71% error on tmax only, 
respectively, which is likely to be protocol based. No 
model fit failed the validation for both reported tmax and 
Cmax values. Overall, the model was reasonably validated 
in whole or in part across 35 of 37 studies with low 
errors. These results show the ability of the model to 
capture the fundamental dynamics of insulin action for 
several insulin types based on data from a wide range of 
studies using a unified consistent PK model.
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